全文获取类型
收费全文 | 987篇 |
免费 | 68篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 71篇 |
妇产科学 | 3篇 |
基础医学 | 132篇 |
口腔科学 | 20篇 |
临床医学 | 62篇 |
内科学 | 79篇 |
皮肤病学 | 21篇 |
神经病学 | 436篇 |
特种医学 | 15篇 |
外科学 | 64篇 |
综合类 | 9篇 |
预防医学 | 42篇 |
眼科学 | 3篇 |
药学 | 63篇 |
中国医学 | 3篇 |
肿瘤学 | 36篇 |
出版年
2023年 | 3篇 |
2022年 | 11篇 |
2021年 | 14篇 |
2020年 | 8篇 |
2019年 | 10篇 |
2018年 | 12篇 |
2017年 | 13篇 |
2016年 | 17篇 |
2015年 | 15篇 |
2014年 | 29篇 |
2013年 | 45篇 |
2012年 | 68篇 |
2011年 | 69篇 |
2010年 | 48篇 |
2009年 | 44篇 |
2008年 | 70篇 |
2007年 | 72篇 |
2006年 | 55篇 |
2005年 | 43篇 |
2004年 | 42篇 |
2003年 | 50篇 |
2002年 | 39篇 |
2001年 | 40篇 |
2000年 | 36篇 |
1999年 | 33篇 |
1998年 | 11篇 |
1997年 | 6篇 |
1996年 | 5篇 |
1995年 | 5篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 16篇 |
1991年 | 19篇 |
1990年 | 13篇 |
1989年 | 14篇 |
1988年 | 11篇 |
1987年 | 13篇 |
1986年 | 13篇 |
1985年 | 14篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 3篇 |
1981年 | 2篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1968年 | 1篇 |
1939年 | 1篇 |
1934年 | 1篇 |
1926年 | 1篇 |
排序方式: 共有1061条查询结果,搜索用时 15 毫秒
31.
Samuel M. Goldman MD MPH Freya Kamel PhD G. Webster Ross MD Sarah A. Jewell MD MPH Connie Marras MD PhD Jane A. Hoppin ScD David M. Umbach PhD Grace S. Bhudhikanok PhD Cheryl Meng MS Monica Korell MPH Kathleen Comyns MPH Robert A. Hauser MD Joseph Jankovic MD Stewart A. Factor DO Susan Bressman MD Kelly E. Lyons PhD Dale P. Sandler PhD J. William Langston MD Caroline M. Tanner MD PhD 《Movement disorders》2014,29(9):1171-1180
Increased gut permeability, inflammation, and colonic α‐synuclein pathology are present in early Parkinson's disease (PD) and have been proposed to contribute to PD pathogenesis. Peptidoglycan is a structural component of the bacterial cell wall. Peptidoglycan recognition proteins (PGRPs) maintain healthy gut microbial flora by regulating the immune response to both commensal and harmful bacteria. We tested the hypothesis that variants in genes that encode PGRPs are associated with PD risk. Participants in two independent case‐control studies were genotyped for 30 single‐nucleotide polymorphisms (SNPs) in the four PGLYRP genes. Using logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) adjusted for potential confounding variables, we conducted analyses in each study, separately and pooled. One SNP failed the assay, and three had little to no variation. The ORs were similar in both study populations. In pooled analyses, three of seven PGLYRP2 SNPs (rs3813135, rs733731, rs892145), one of five PGLYRP3 SNPs (rs2987763), and six of nine PGLYRP4 SNPs (rs10888557, rs12063091, rs3006440, rs3006448, rs3006458, and rs3014864) were significantly associated with PD risk. Association was strongest for PGLYRP4 5'untranslated region (UTR) SNP rs10888557 (GG reference, CG OR 0.6 [95%CI 0.4‐0.9], CC OR 0.15 [95%CI 0.04‐0.6]; log‐additive P‐trend, 0.0004). Common variants in PGLYRP genes are associated with PD risk in two independent studies. These results require replication, but they are consistent with hypotheses of a causative role for the gut microbiota and gastrointestinal immune response in PD. © 2014 International Parkinson and Movement Disorder Society 相似文献
32.
Zecca M Nobili B Ramenghi U Perrotta S Amendola G Rosito P Jankovic M Pierani P De Stefano P Bonora MR Locatelli F 《Blood》2003,101(10):3857-3861
Autoimmune hemolytic anemia (AIHA) in children is sometimes characterized by a severe course, requiring prolonged administration of immunosuppressive therapy. Rituximab is able to cause selective in vivo destruction of B lymphocytes, with abrogation of antibody production. In a prospective study, we have evaluated the use of rituximab for the treatment of AIHA resistant to conventional treatment. Fifteen children with AIHA were given rituximab, 375 mg/m(2)/dose for a median of 3 weekly doses. All patients had previously received 2 or more courses of immunosuppressive therapy; 2 patients had undergone splenectomy. After completing treatment, all children received intravenous immunoglobulin for 6 months. Treatment was well tolerated. With a median follow-up of 13 months, 13 patients (87%) responded, whereas 2 patients did not show any improvement. Median hemoglobin levels increased from 7.7 g/dL to a 2-month posttreatment level of 11.8 g/dL (P <.001). Median absolute reticulocyte counts decreased from 236 to 109 x 10(9)/L (P <.01). An increase in platelet count was observed in patients with concomitant thrombocytopenia (Evans syndrome). Three responder patients had relapse, 7, 8, and 10 months after rituximab infusion, respectively. All 3 children received a second course of rituximab, again achieving disease remission. Our data indicate that rituximab is both safe and effective in reducing or even abolishing hemolysis in children with AIHA and that a sustained response can be achieved in the majority of cases. Disease may recur, but a second treatment course may be successful in controlling the disease. 相似文献
33.
Wendy R. Galpern Christopher S. Coffey Alberto Albanese Ken Cheung Cynthia L. Comella Dixie J. Ecklund Stanley Fahn Joseph Jankovic Karl Kieburtz Anthony E. Lang Michael P. McDermott Jeremy M. Shefner Jan K. Teller John L. P. Thompson Sharon D. Yeatts H. A. Jinnah 《Neurotherapeutics》2014,11(1):117-127
With advances in the understanding of the pathophysiology of dystonia, novel therapeutics are being developed. Such therapies will require clinical investigation ranging from exploratory studies to examine safety, tolerability, dosage selection, and preliminary efficacy to confirmatory studies to evaluate efficacy definitively. As dystonia is a rare and complex disorder with clinical and etiological heterogeneity, clinical trials will require careful consideration of the trial design, including enrollment criteria, concomitant medication use, and outcome measures. Given the complexities of designing and implementing efficient clinical trials, it is important for clinicians and statisticians to collaborate closely throughout the clinical development process and that each has a basic understanding of both the clinical and statistical issues that must be addressed. To facilitate designing appropriate clinical trials in this field, we review important general clinical trial and regulatory principles, and discuss the critical components of trials with an emphasis on considerations specific to dystonia. Additionally, we discuss designs used in early exploratory, late exploratory, and confirmatory phases, including adaptive designs. 相似文献
34.
35.
36.
37.
38.
Cranial computed tomography findings in children with acute lymphoblastic leukemia at diagnosis 总被引:1,自引:0,他引:1
M Jankovic F Zanetto V Conter M Tagliabue F Agostoni I Macchi G Masera 《The American journal of pediatric hematology/oncology》1989,11(3):327-329
Forty children newly diagnosed with acute lymphoblastic leukemia (ALL) were examined by computed tomography (CT) of the central nervous system (CNS) on hospital admission before any medication was started. The results of the CT scans were defined as normal, borderline (slight or moderate dilatation of the ventricular system and/or basal cisterns and/or convolutional sulci), or pathologic (severe cerebral atrophy). The mean age of the patients was 5.8 years (range 1.7-15 years). Sixteen of the 40 patients (40%) had CT scan abnormalities with 14 patients having borderline scans and two patients pathologic scans. No child presented with neurologic symptoms or CNS leukemia. These data suggest that CT abnormalities of the brain are common in children with ALL at diagnosis and may represent clinically unsuspected lesions secondary to leukemia. 相似文献
39.
Valentino Conter Paolo D'Angelo Attilio Rovelli Cornelio Uderzo Momcilo Jankovic Giorgio Bratina Giuseppe Masera 《Pediatric blood & cancer》1992,20(2):165-168
Unusual sites of relapses following bone marrow transplantation (BMT) for childhood acute lymphoblastic leukemia (ALL) are rarely reported. We report the case of a 16-year-old girl who presented with an isolated right breast relapse 8 months after allogeneic BMT for ALL in second remission. Biopsy showed an ALL infiltrate. Bone marrow and CSF were normal. The girl never showed before extramedullary involvement. She was treated with local radiotherapy and mild systemic chemotherapy. Nine months after breast relapse, she presented an isolated central nervous system relapse. The treatment of isolated extramedullary relapses following BMT is still controversial. 相似文献
40.
Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report 总被引:1,自引:0,他引:1
R H Miller G E Woodson J Jankovic 《Archives of otolaryngology--head & neck surgery》1987,113(6):603-605
A number of different therapies have been used in the management of spasmodic dysphonia. None are curative, and the results of the most widely used surgical procedure (resection of the recurrent laryngeal nerve) are not universally good, with a high recurrence rate in some series. Furthermore, the procedure is not reversible. Using a special electromyographic hypodermic needle, we injected botulinum A toxin into one of the vocal folds of two patients with severe spasmodic dysphonia. Both had significant improvement without any complications. Although the resultant paresis is not permanent, the injection can be repeated as needed as an outpatient procedure. 相似文献